NEW YORK and PARIS, March 26, 2025 /PRNewswire/ — Rarecells Inc., a pioneering company in liquid biopsy technology, is pleased to announce the appointment of Dr. Neil Kurtz to its Board of Directors. Dr. Kurtz, a renowned healthcare entrepreneur and executive, brings over 40 years of experience in the pharmaceutical, contract research, post-acute care, and medical diagnostic sectors.
Dr. Kurtz has a distinguished career as a founder of several successful companies, including Medidata Systems and Worldwide Clinical Trials, which collectively generated over $8 billion in value for investors. He has served as CEO of both public and private companies and has held senior executive positions in top pharmaceutical and healthcare organizations. His leadership experience includes serving as President and CEO of Golden Living, one of the United States’ largest providers of diversified care.
“We are delighted to welcome Dr. Kurtz to our Board of Directors,” said Dr. Patrizia Paterlini, CEO of Rarecells Inc. “His extensive expertise in diagnostics, finance, and scientific research, along with his strategic insights, will be invaluable as we continue to develop and commercialize our innovative liquid biopsy technology for early cancer detection. His addition strengthens our commitment to assembling a board with significant expertise to guide our mission of delivering unparalleled, label-free access to intact circulating tumor cells and their CTC-DNA for downstream analysis. We are confident that Dr. Kurtz’s leadership will further enhance our efforts to bring cutting-edge solutions to the forefront of precision oncology.”
“I am honored to join the already exceptional Board of Directors at Rarecells,” said Dr. Kurtz. “I am aligned with the company’s belief that through its ISET technology it has the potential to revolutionize cancer diagnostics and personalized treatment, having a profound impact on the lives of millions of patients worldwide. I look forward to sharing the insights I have gained across my industry experience and contributing to Rarecells’ growth and success in this critical field, where the unmet need remains critical.”
Dr. Kurtz is the 5th member of Rarecells’ Board of Directors. The other members are Patrizia Paterlini MD, PhD, President, CEO & Founder of Rarecells; Neil Gunn, PhD, former head of Roche Molecular Systems and Roche Sequencing, Christian Brechot MD, PhD, Senior Associate Dean for Research in Global Affairs and the Associate Vice-President for International Partnerships and Innovation at the University of South Florida, Tampa & President of the Global Virus Network; Thierry de Marignac, Former Partner at Banque Mirabaud & Cie & Leading Investor.
About Rarecells Inc.
Rarecells Inc. is a leading company in the development of innovative non-invasive tests for early cancer diagnosis based on a proprietary hypersensitive AI-based Circulating Tumor Cells (CTCs) and CTC-DNA detection. Founded in 2012, the firm is headquartered in New York with offices and laboratories in New York and Paris. For more information, visit www.rarecells.com
Contact: media@rarecells.com
Photo – https://healthtechnologynet.com/wp-content/uploads/2025/03/Neil_Kurtz.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2025/03/Rarecells_Logo.jpg
SOURCE Rarecells, Inc.
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…